Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 3/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21133324 | 0.83 | ALDH1A1 (0.38) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL24191276 | 0.82 | P2RX3 (0.40) | ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL21362282 | 0.81 | ALDH1A1 (0.44) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL21132765 | 0.79 | ALDH1A1 (0.38) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL21132756 | 0.79 | ALDH1A1 (0.38) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL26558641 | 0.78 | AURKA (0.30) | — | |
| SCHEMBL21132949 | 0.74 | ALDH1A1 (0.69) | ALDH1A1LMNAALBMAPK1TYMP | |
| SCHEMBL21417395 | 0.74 | ALDH1A1 (0.69) | ALDH1A1LMNAALBMAPK1TYMP | |
| SCHEMBL21362217 | 0.74 | ALDH1A1 (0.46) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL22219806 | 0.73 | TAS1R3 (0.54) | ALDH1A1LMNAALBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | STING1, CGAS, TLR9 | ALDH1A1 3436/4885LMNA 3340/4885ALB 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.